Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452190 · ClinicalTrials.gov registry record · Phase 3
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A Phase 3 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 468
- Enrollment target
- 20
- Study locations
NCT02452190 is a Phase 3 study of Asthma that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 468 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT02452190, a Phase 3 study of Asthma, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 468 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Reslizumab
Study Locations (20)
California
- Teva Investigational Site 13215 - Bakersfield
- Teva Investigational Site 13181 - Canoga Park
- Teva Investigational Site 13254 - Fresno
- Teva Investigational Site 13216 - Huntington Beach
- Teva Investigational Site 13247 - Long Beach
- Teva Investigational Site 13205 - Napa
- Teva Investigational Site 13764 - San Jose
- Teva Investigational Site 13252 - Stockton
- Teva Investigational Site 13251 - Walnut Creek
Florida
- Teva Investigational Site 13196 - Aventura
- Teva Investigational Site 13256 - Fort Lauderdale
- Teva Investigational Site 13203 - Kissimmee
- Teva Investigational Site 13197 - Miami
- Teva Investigational Site 13220 - Miami
- Teva Investigational Site 13243 - Miami
Alabama
- Teva Investigational Site 13212 - Birmingham
Arizona
- Teva Investigational Site 13241 - Flagstaff
Arkansas
- Teva Investigational Site 13194 - Glendale
Colorado
- Teva Investigational Site 13229 - Denver
Connecticut
- Teva Investigational Site 13766 - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452190
The ClinicalTrials.gov registry entry for NCT02452190 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (70% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02452190 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02452190 about?
NCT02452190 is a clinical study titled "Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils". The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.
What is the current status of trial NCT02452190?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 468 participants. The study started on 2015-09-28. Estimated completion is 2018-01-31.
What conditions does trial NCT02452190 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02452190?
The interventions under investigation include: Placebo (DRUG), Reslizumab (DRUG).
Who is sponsoring clinical trial NCT02452190?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02452190 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.